Immunotherapy Approved in Combination With BCG for High-risk Bladder Cancer
The FDA approved durvalumab with Bacillus-Calmette Guérin for patients with high-risk, BCG-naïve non-muscle invasive bladder cancer. The U.S. Food...
Progress Against Cancer
The FDA approved durvalumab with Bacillus-Calmette Guérin for patients with high-risk, BCG-naïve non-muscle invasive bladder cancer. The U.S. Food...
The FDA approved pivekimab sunirine-pvzy for the treatment of the rare blood cancer BPDCN. The U.S. Food and Drug...
Datopotamab deruxtecan-dlnk was approved to treat PD-1/PD-L1 inhibitor-ineligible, advanced triple-negative breast cancer. The U.S. Food and Drug Administration (FDA)...
The FDA has approved fam-trastuzumab deruxtecan-nxki for neoadjuvant or adjuvant treatment of HER2-positive early-stage breast cancer. The U.S. Food...
The FDA has approved atezolizumab or atezolizumab and hyaluronidase-tqjs as adjuvant therapy for muscle-invasive bladder cancer. The U.S. Food...
The FDA approved oral decitabine and cedazuridine with venetoclax for newly diagnosed acute myeloid leukemia in older patients. The...
The BCL-2 inhibitor received accelerated approval for patients with relapsed or refractory mantle cell lymphoma. The U.S. Food and...
The bispecific antibody was approved for certain patients whose bile duct cancer harbors gene fusions that involve the neuregulin...
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant...
Relacorilant was approved for previously treated ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA)...